期刊文献+

Phase Ⅲ trial of docetaxel cisplatin 5-fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome 被引量:2

原文传递
导出
摘要 Dear Editor,Induction chemotherapy has been utilized for decades in locally advanced head and neck squamous cell carcinoma(HNSCC).The docetaxel,cisplatin,5-fluorouracil(TPF)regimen is the most recommended induction chemotherapy regimen forHNSCC and oral squamous cell carcinoma(OSCC)[1].However,our initial phase Ⅲ trial failed to demonstrate a significant survival benefit of TPF induction chemotherapy in patients with locally advanced OSCC[2].
出处 《Cancer Communications》 SCIE 2021年第3期279-283,共5页 癌症通讯(英文)
基金 supported by the National Natural Science Foundation of China(81972525,81672660) the Shanghai Municipal Education Commission(17SG18) the Shanghai Municipal Commission of Health and Family Planning(2018BR41) the Programof Shanghai Academic/Technology Research Leader(19XD1422300) Shanghai Jiao Tong University School of Medicine(201916,20191915).
  • 相关文献

同被引文献2

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部